HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by SURWIT, E. A. Articles by GRAHAM, V. E. Search for Related Content PubMed PubMed Citation Articles by SURWIT, E. A. Articles by GRAHAM, V. E.

Poor-Prognosis Gestational Trophoblastic Disease

An Update

From the Department of Obstetrics and Gynecology, the Department of Medicine, Section of Hematology/Oncology, and the Southwestern Regional Trophoblastic Disease Center, University of Arizona Health Sciences Center, Tucson, Arizona.

Ten patients with poor-prognosis gestational trophoblastic neoplasia were treated from 1979 to 1983 primarily with the modified Bagshawe chemotherapy regimen. Four patients were noted to have brain metastases, and one patient had liver metastases. In addition, etoposide (VP-16) was used in seven patients, bleomycin in six, cisplatin in five, 5-fluoro-uracil in two, and cis-retinoic acid in four patients. Thoracotomy, hysterectomy, and splenectomy were performed after chemotherapy was initiated for isolated resistant disease. At present, nine of the ten patients (90%) are in complete remission for four to 44 months. Significant myelosuppression was encountered in seven patients and life-threatening toxicity was noted in two patients. Currently, poor-prognosis patients are treated with the modified Bagshawe regimen, alternating every other week with etoposide, bleomycin, and cisplatin.